Fierce Pharma
APRIL 24, 2024
It’s been eight months since Regeneron secured approval for a high-dose version of its powerhouse macular degeneration treatment Eylea in the U.S. | How much impact has the approval of high-dose Eylea had on the upward trajectory of Roche’s Vabysmo? Not much, according to sales figures released by Roche.
MedCity News
APRIL 24, 2024
More than 33,000 Providence employees filed a class-action complaint against the health system in 2021, alleging that it had been withholding their wages by denying them breaks and rounding down their working hours. Last week, Providence was ordered to pay more than $200 million in damages — a decision that “sends a message to healthcare corporations,” according to an attorney representing the workers.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
APRIL 24, 2024
While Biogen’s Chris Viehbacher figures the company is “turning the corner” after several recent setbacks—thanks in large part to accelerating launches of new drugs like Leqembi and Skyclarys—the C | While Biogen’s Chris Viehbacher figures the company is “turning the corner” after several recent setbacks, the CEO admitted Wednesday that there’s still “a lot of work to do” as the biotech plugs ahead with its “Fit for Growth” savings initiative.
Pharmaceutical Technology
APRIL 24, 2024
Pfizer and its Germany partner BioNTech have urged London’s High Court to invalidate competitor Moderna's patents over technology instrumental in the Covid-19 vaccines development as the latest phase of a global legal fight that started yesterday (23 April), reported Reuters.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
MedCity News
APRIL 24, 2024
Game-changing advances can be achieved by integrating patient collaboration and priorities into the full span of trial design. The post It’s Time to Give Patients a Seat at the Table appeared first on MedCity News.
pharmaphorum
APRIL 24, 2024
A new FDA initiative is seeing how augmented reality and virtual reality (AR/VR) can make patients’ own homes an integral part of the healthcare system
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
pharmaphorum
APRIL 24, 2024
An oral therapy that can allow children and adolescents with an aggressive form of brain cancer to be treated at home rather than in hospital has been recommended for use by the NHS in England and Wales.
MedCity News
APRIL 24, 2024
Day One Biopharmaceuticals drug Ojemda is now FDA-approved for advanced pediatric low-grade glioma, the most common type of brain cancer in children. The regulatory decision for Ojemda covers a broader swath of patients than a drug combination from Novartis approved for treating this childhood cancer. The post FDA Drug Approval Marks a New Day for Treating Pediatric Brain Cancer appeared first on MedCity News.
pharmaphorum
APRIL 24, 2024
Endeavor BioMedicines raises $132.
Pharmaceutical Commerce
APRIL 24, 2024
The latest news for pharma industry insiders.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
pharmaphorum
APRIL 24, 2024
Alzheimer’s drug Leqembi moves forward, still in low gear Phil.
MedCity News
APRIL 24, 2024
Algorithms make it possible for companies to fix prices without explicitly coordinating with one another, posing a new test for regulators policing the market, said Lina Khan, chair of the Federal Trade Commission, during a media event hosted by KFF. The post FTC Chief Says Tech Advancements Risk Healthcare Price Fixing appeared first on MedCity News.
pharmaphorum
APRIL 24, 2024
Roche chief executive Thomas Schinecker said today that one in five of the pharma division’s pipeline of new molecular entities (NMEs) has been culled in the last few months as part of a shift in focus on “high impact” projects.
European Pharmaceutical Review
APRIL 24, 2024
Researchers have evaluated microbial contamination surface sampling methods to assess the recovery efficacy of naturally occurring microbe-carrying particles (MCPs). Sterile tryptone soya agar 55mm diameter tryptone soya agar RODAC contact plates were used in the investigation. Three different manual sampling methods were tested on contaminated hard surfaces containing MCPs dispersed from a person within heavily populated environments.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
pharmaphorum
APRIL 24, 2024
New biotech Xaira Therapeutics emerges with $1bn in funding for its plan to apply AI to drug discovery in ways hard to achieve with conventional technologies
European Pharmaceutical Review
APRIL 24, 2024
in clinical trials [the combination treatment was shown] to halt tumour growth for low-grade gliomas for an average of more than two years” The National Institute for Health and Care Excellence (NICE) has recommended a new targeted drug combination treatment for young people with BRAF V600E mutation-positive glioma. Dabrafenib (Finlee) in combination with trametinib (Spexotras) is indicated for patients aged one and over, based on the agency’s proposal in its final draft guidance.
PharmaTimes
APRIL 24, 2024
According to the World Health Organization, CVDs are responsible for an estimated 17.
pharmaphorum
APRIL 24, 2024
BeiGene has claimed a second EU approval for PD-1 inhibitor tislelizumab in non-small cell lung cancer (NSCLC), opening the door to the first launches of the drug outside China. The new approval covers three separate indications for the drug, alone and in combination with chemotherapy for squamous and non-squamous forms of NSCLC, and covering first- and second-line therapy.
PharmaTimes
APRIL 24, 2024
The progressive neurodegenerative condition is the most common form of dementia
MedCity News
APRIL 24, 2024
Success requires both novel VBC models as well as moving care beyond the clinic walls to meet patients where they are. The post Patient Engagement Is Essential for Achieving the Goals of Value-Based Care appeared first on MedCity News.
PharmaTech
APRIL 24, 2024
FDA has granted approval for the use of Novartis’ radioligand therapy, Lutathera, to treat pediatric patients with gastroenteropancreatic neuroendocrine tumors.
MedCity News
APRIL 24, 2024
The MedCity INVEST conference is scheduled for May 21-22 at the Ritz Carlton hotel in Chicago, The companies will offer a window into some of the promising treatments under development such as different types of cancers to muscular dystrophy. Space is limited so register today! The post Six Biopharma Companies to Watch at MedCity INVEST Pitch Perfect Contest appeared first on MedCity News.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
Pharmacy Times
APRIL 24, 2024
Multiple state and federal laws since the COVID-19 pandemic highlight the growing role of technicians
MedCity News
APRIL 24, 2024
it is paramount that we address both cholesterol risk and inflammation to reduce the risk of a heart attack or stroke. The post To Further Impede the Progression of Heart Disease, We Must Treat Patients With Anti-Inflammatory Drugs in Combination With Statin Therapy appeared first on MedCity News.
PharmaVoice
APRIL 24, 2024
While the company is eager to diversify, CEO Chris Viehbacher said that in the near-term any dealmaking would likely focus on collaborations and early-stage assets.
Pharmaceutical Technology
APRIL 24, 2024
Incyte has agreed to acquire US-based Escient Pharmaceuticals and its assets including two first-in-class small molecule antagonists targeting Mas-related G protein-coupled receptor X2 (MRGPRX2) for the treatment of various mast cell-mediated disorders.
Pharmacy Times
APRIL 24, 2024
Pivmecillinam (Pivya) tablets were approved for female adults with uncomplicated urinary tract infection caused by Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus.
PharmaTech
APRIL 24, 2024
Developing freeze-drying processes requires patience and deep product and process understanding.
Pharmacy Times
APRIL 24, 2024
The recombinant zoster vaccine demonstrated a 79.7% efficacy in patients aged 50 years and older cumulatively within the 6- to 11-year period after vaccination.
PharmExec
APRIL 24, 2024
In an interview with Pharm Exec Associate Editor Don Tracy, Howard Berman, Chairman, CEO, Coya Therapeutics offers a preview on what the nexts steps are after presenting positive data on Coya 302 for the treatment of ALS.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
306 
Let's personalize your content